H.C. Wainwright lowered the firm’s price target on TuHURA Biosciences (HURA) to $12 from $13 and keeps a Buy rating on the shares following the Q4 report.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Announces Acquisition of Kineta, Inc.
- TuHURA Biosciences Expands Board with New Appointment
- TuHURA Biosciences appoints Craig Tendler to board of directors
- Dollar General downgraded, Oracle upgraded: Wall Street’s top analyst calls
- TuHURA Biosciences initiated with a Buy at H.C. Wainwright